All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How should we monitor risk of progression in patients achieving MRD negativity after auto-SCT?

Featured
Sep 2, 2020
Share:

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra, Pamplona, ES, about the importance of monitoring measurable residual disease (MRD) status.

How should we monitor risk of progression in patients achieving MRD negativity after auto-SCT?

We asked, How should we monitor risk of progression in patients achieving MRD negativity after autologous stem cell transplant?

Share: